An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer

Peking University

Status: Unknown

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Other

Identifiers

NCT01860144

CGOG2001

Details and patient eligibility

About

This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.

Enrollment: 250 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed metastatic colorectal cancer patients Having initiated treatment with bevacizumab

Exclusion criteria

• non-metastatic colorectal cancer patients not recieved bevacizumab

Trial design

250 participants in 1 patient group

bevacizumab

Description:

Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab

Treatment:

Drug: Bevacizumab